Table 3 Cardiovascular toxicities documented during cardio oncology clinic assessment

Hypertension

12

34

0

Not present

23

66

1

Systolic/diastolic blood pressure > 90th percentile but <95th percentile

10

29

2

Systolic/diastolic blood pressure > 95th percentile but <99th centile

2

6

3

Systolic/diastolic blood pressure > 5mmhg above 99th percentile

0

0

4

Life threatening consequences (i.e., malignant hypertension)

0

0

QTc Prolongation

2

6

0

Not present

33

94

1

Average QTc 450 – 480 ms

2

6

2

Average QTc 481 – 500 ms

0

0

3

Average QTc ≥ 501 ms; > 60 ms change from baseline

0

0

4

Torsades de pointes; polymorphic ventricular tachycardia etc

0

0

Left Ventricular Systolic Dysfunction or Ejection Fraction Decreased

9

24.3

0

Not present

27

77

1

Ejection Fraction Decreased < 50–40% or < 10–19% drop from baseline

4

11

2

Ejection Fraction Decreased 50–40% or 10–19% drop from baseline

1

3

3

Symptomatic due to drop in ejection fraction responsive to intervention

3

9

4

Refractory or poorly controlled heart failure due to drop in ejection fraction; intervention such as ventricular assist device, vasopressor support or heart transplant indicated

0

0

Atrioventricular Block First degree

1

2.7

0

Not present

36

97.3

1

Asymptomatic, intervention not indicated

1

3

2

Non-urgent intervention indicated

0

0

Aortic Valve Disease

1

2.7

0

Not present

36

0

1

Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging

1

3

2

Asymptomatic; moderate regurgitation or stenosis by imaging

0

0

3

Symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention

0

0

4

Life-threatening consequences; urgent intervention indicated (i.e., valve replacement, valvuloplasty)

0

0